Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 6/2016

01-06-2016 | Sarcomas (SR Patel, Section Editor)

Advances in Radiation Therapy for Primary and Metastatic Adult Soft Tissue Sarcomas

Authors: Philip Blumenfeld, Neilayan Sen, Ross Abrams, Dian Wang

Published in: Current Oncology Reports | Issue 6/2016

Login to get access

Abstract

Soft tissue sarcomas (STS) consist of a heterogeneous group of rare malignancies arising from mesenchymal origin. While surgical resection is the primary treatment for STS, the use of radiotherapy (RT) as an adjunctive modality has been shown to improve oncologic outcomes. Technologic improvements, such as image guidance and intensity-modulated radiotherapy that significantly improve both the precision and delivery of RT, have led to the reduction of long-term RT toxicities without compromising outcomes. This review addresses these technologic advancements as well as discussing the most current updates regarding the use of brachytherapy, charged particles, and novel agents with RT.
Literature
1.
2.
Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization classification of tumors: pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002.
3.
Lawrence Jr W, Donegan WL, Natarajan N, et al. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg. 1987;205(4):349–59.CrossRefPubMedPubMedCentral
4.
Enneking WF, Spanier SS, Malawar MM. The effect of the anatomic setting on the results of surgical procedure for soft parts sarcoma of the thigh. Cancer. 1981;47(5):1005–22.CrossRefPubMed
5.
Riad S, Griffin AM, Liberman B, et al. Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res. 2004;426:129–34.CrossRefPubMed
6.
Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305–15.CrossRefPubMedPubMedCentral
7.
Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14(3):859–68.PubMed
8.
Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16(1):197–203.PubMed
9.
Gitelis S, Thomas R, Templeton A, Schajowicz F. Characterization of the pseudocapsule of soft-tissue sarcomas. An experimental study in rats. Clin Orthop Relat Res. 1989;246:285–92.PubMed
10.
Davis AM, O’Sullivan B, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75:48–53.CrossRefPubMed
11.
O’Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359:2235–41.CrossRefPubMed
12.•
Wang D, Bosch W, Roberge D, et al. RTOG sarcoma radiation oncologists reach consensus on gross tumor volume and clinical target volume on computed tomographic images for preoperative radiotherapy of primary soft tissue sarcoma of extremity in Radiation Therapy Oncology Group studies. Int J Radiat Oncol Biol Phys. 2011;81(4):e525–8. In this article, a group of RTOG sarcoma radiation oncology experts have reached a consensus on how to contour gross tumor volume and clinical target volume for preoperative radiation treatment of primary extremity soft tissue sarcoma. Detailed description and images were also published in the RTOG website Core Lab Contouring Atlas https://​www.​rtog.​org/​LinkClick.​aspx?​fileticket=​AThtvc6dabE%3d&​tabid=​356.
13.
Halperin EC. Intensity-modulated radiation treatment techniques and clinical applications. In: Perez and Brady’s principles and practice of radiation oncology. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008. Print.
14.
Alektiar KM, Brennan MF, Healey JH, Singer S. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. J Clin Oncol. 2008;26(20):3440–4.CrossRefPubMed
15.
O’Sullivan B, Griffin AM, Dickie CI, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer. 2013;119(10):1878–84.CrossRefPubMed
16.••
Wang D, Zhang Q, Eisenberg BL, et al. Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: results of radiation therapy oncology group RTOG-0630 trial. J Clin Oncol. 2015;33(20):2231–8. Results of a multi-institutional phase II trial of image-guided preoperative radiation treatment for primary extremity soft tissue sarcoma (RTOG 0630) have demonstrated a significant reduction in late toxicity in extremity STS patients treated with preoperative IG-RT to a reduced target volume when compared to the NCIC SR2 trial. Excellent local control, the absence of marginal-field recurrences, and the favorable late toxicity profile suggest that the parameters used in this protocol are appropriate for preoperative IG-IMRT for extremity STS. This is a sarcoma research milestone publication.CrossRefPubMed
17.
Alektiar KM, Leung D, Zelefsky MJ, Healey JH, Brennan MF. Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity. Ann Surg Oncol. 2002;9(1):48–56.CrossRefPubMed
18.
Alektiar KM, Brennan MF, Singer S. Local control comparison of adjuvant brachytherapy to intensity-modulated radiotherapy in primary high-grade sarcoma of the extremity. Cancer. 2011;117(14):3229–34.CrossRefPubMed
19.
Mendenhall WM, Indelicato DJ, Scarborough MT, et al. The management of adult soft tissue sarcomas. Am J Clin Oncol. 2009;32(4):436–42.CrossRefPubMed
20.
Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998;228(3):355–65.CrossRefPubMedPubMedCentral
21.
Feng M, Murphy J, Griffith KA, et al. Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma. Int J Radiat Oncol Biol Phys. 2007;69(1):103–10.CrossRefPubMed
22.
Gieschen HL, Spiro IJ, Suit HD, et al. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2001;50(1):127–31.CrossRefPubMed
23.
Ballo MT, Zagars GK, Pollock RE, Benjamin RS, Feig BW, Cormier JN, et al. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys. 2007;67(1):158–63.CrossRefPubMed
24.
Tzeng CW, Fiveash JB, Popple RA, et al. Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma. Cancer. 2006;107(2):371–9.CrossRefPubMed
25.
26.
Baldini BH, Bosch W, Kane III JM, et al. Retroperitoneal sarcoma (RPS) High risk gross tumor volume boost (HR GTV Boost) contour delineation agreement among NRG sarcoma radiation and surgical oncologists. Ann Surg Oncol. 2015. doi:10.​1245/​s10434-015-4633-x.PubMedCentral
27.
Baldini EH, Abrams RA, Bosch W, et al. Retroperitoneal sarcoma target volume and organ at risk contour delineation agreement among NRG sarcoma radiation oncologists. IJROBP. 2015;92(5):1053–9. doi:10.​1016/​j.​ijrobp.​2015.​04.​039. Epub 2015 May 1.PMID:26194680.
28.
Yoon SS, Chen YL, Kirsch DG, et al. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. Ann Surg Oncol. 2010;17(6):1515–29.CrossRefPubMedPubMedCentral
29.
Yoon SS, Duda DG, Karl DL, et al. Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2011;81(4):1081–90.CrossRefPubMedPubMedCentral
30.
Sleijfer S, Ray-coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126–32.CrossRefPubMed
31.•
Wong P, Houghton P, Kirsch DG, et al. Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J Natl Cancer Inst. 2014;106(11). In this article, a group of NRG Oncology sarcoma experts focused on translational research has worked with the NCI Radiation Research Program and Molecular Pharmacology Branch to establish positional statements on investigation of targeted agents in combination with radiation treatment of sarcoma.
32.
Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999;229(5):602–10.CrossRefPubMedPubMedCentral
33.
Burt BM, Ocejo S, Mery CM, et al. Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival. Ann Thorac Surg. 2011;92(4):1202–7.CrossRefPubMed
34.
Miyamoto C. (Chairperson & Professor, Department of Radiation Oncology, Temple University School of Medicine) Personal communication. 2010;23:51.
35.
Dhakal S, Corbin KS, Milano MT, et al. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. Int J Radiat Oncol Biol Phys. 2012;82(2):940–5.CrossRefPubMed
36.
Mehta N, Selch M, Wang PC, et al. Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma. Sarcoma. 2013;2013:360214.CrossRefPubMedPubMedCentral
37.
Soyfer V, Corn BW, Shtraus N, et al. Single-institution Experience of SBRT for lung metastases in sarcoma patients. Am J Clin Oncol. 2014. [Epub ahead of print].
38.
Navarria P, Ascolese AM, Cozzi L, et al. Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. Eur J Cancer. 2015;51(5):668–74.CrossRefPubMed
Metadata
Title
Advances in Radiation Therapy for Primary and Metastatic Adult Soft Tissue Sarcomas
Authors
Philip Blumenfeld
Neilayan Sen
Ross Abrams
Dian Wang
Publication date
01-06-2016
Publisher
Springer US
Published in
Current Oncology Reports / Issue 6/2016
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-016-0523-z

Other articles of this Issue 6/2016

Current Oncology Reports 6/2016 Go to the issue

Melanoma (RJ Sullivan, Section Editor)

Cell Cycle Regulation and Melanoma

Integrative Care (C Lammersfeld, Section Editor)

Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)

Cardio-oncology (EH Yang, Section Editor)

Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?

Cardio-oncology (EH Yang, Section Editor)

Exercise Training in Cancer Survivors

Cardio-oncology (EH Yang, Section Editor)

Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management

Leukemia (A Aguayo, Section Editor)

Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits